SCHEDULE 13G: Vanguard Group Discloses 5.06% Passive Stake in Applied Therapeutics Inc

The Vanguard Group has filed a Schedule 13G, reporting a 5.06% beneficial ownership stake in Applied Therapeutics Inc as of March 31, 2025.

Summary

• The Vanguard Group, a major investment adviser based in Pennsylvania, has filed a Schedule 13G with the SEC.
• The filing indicates that Vanguard beneficially owns 5,889,193 shares of Common Stock in Applied Therapeutics Inc.
• This aggregate amount represents 5.06% of the class of securities.
• Vanguard holds sole voting power over 0 shares, shared voting power over 78,383 shares, sole dispositive power over 5,780,081 shares, and shared dispositive power over 109,112 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Applied Therapeutics Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by a major institutional investor, which can be viewed as a vote of confidence and a positive signal of institutional interest, though it does not imply active management involvement or specific operational improvements.

Positives

• The disclosure of a significant 5.06% stake by a major institutional investor like The Vanguard Group can be interpreted as a vote of confidence in Applied Therapeutics Inc.
• Increased institutional ownership can enhance the company's visibility and potentially improve liquidity for its stock.

Future Outlook

The Schedule 13G filing does not contain any forward-looking statements or guidance regarding Applied Therapeutics Inc's future performance or strategic direction, as it is a disclosure of passive beneficial ownership.

Industry Context

This filing is a routine disclosure for large institutional investors like The Vanguard Group when their beneficial ownership in a public company's stock crosses a certain threshold (typically 5%). It reflects a passive investment strategy, common among index funds and broad market portfolios, rather than an active attempt to influence corporate control or strategy. Such disclosures are standard practice in the financial industry to maintain transparency in ownership structures.

Stakeholder Impact

• Shareholders: The presence of a large, passive institutional investor like Vanguard can provide a degree of stability and liquidity to the stock, potentially attracting further institutional interest.

Key Dates

Keywords

Applied Therapeutics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Investment